immune related adverse events
Conditions
Interventions
case series:No
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.It met the diagnostic criteria for the indications of carrelizumab and was clearly diagnosed by pathological examination; 2.Hodgkin's lymphoma, advanced hepatocellular carcinoma and liver cancer treated with or to be treated with camrelizumab alone or in combination; Patients with metastatic NSCLC, esophageal squamous cell carcinoma and nasopharyngeal carcinoma; 3.Aged 18 - 70 years; 4.KPS score >= 60, estimated survival >= 3 months; 5.Volunteers must give informed consent to the study before the test and sign the informed consent form before screening.
Exclusion criteria
Exclusion criteria: 1.Poor compliance during clinical research and failure to cooperate with follow-up and TDM blood sample collection; 2.No definite pathological diagnosis; 3.Receiving camrelizumab alone or combined chemotherapy for >= 12 months; 4.Subjects who did not implement the provisions of this experimental protocol and received carilizumab on schedule; 5.Subjects whose observation items are incomplete and unable to evaluate the occurrence of Irae; 6.Patients with severe immune related adverse drug reactions and drug withdrawal in the past, such as gastrointestinal discomfort caused by drugs; 7.During the follow-up period, the use of calizumab was stopped.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum camrelizumab concentration; | — |
Countries
China
Contacts
Public ContactWang Zhuo
Shanghai Changhai Hospital
Outcome results
None listed